Tumor aggressiveness and patient outcome in cancer of the pancreas assessed by dynamic18F-FDG PET/CT

Journal of Nuclear Medicine

Volumn 54, Issue 1, 2013, Pages 12-18

  Epelbaum, Ron ^a   Frenkel, Alex ^a   Haddad, Riad ^b   Sikorski, Natalia ^c   Strauss, Ludwig G ^d   Israel, Ora ^a   Dimitrakopoulou Strauss, Antonia ^d  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b CARMEL MEDICAL CENTER   (Israel)

^c Lin Medical Center   (Israel)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

18F FDG influx; Dynamic 18F FDG PET; Pancreatic cancer; Survival

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BLOOD VOLUME; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEPHOSPHORYLATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TUMOR LOCALIZATION;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KINETICS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS;

EID: 84872027502     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.107466     Document Type: Article

References (27)

1. National Cancer Institute. Surveillance Epidemiology and End Results. Cancer Statistics. Available at: http://seer.cancer.gov/statistics. Accessed November 9, 2012.
2. Hsu CC, Herman JM, Corsini MM, et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol. 2010;17:981-990.
3. Goulart BH, Clark JW, Lauwers GY, et al. Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: A retrospective analysis. J Hematol Oncol. 2009;2:13.
4. 18FDG PET scanning in oncology. Br J Cancer. 2008;98:1597-1601.
5. Strauss LG, Dimitrakopoulou-Strauss A, Kontaxakis G, et al. PET data processing and image evaluation on PC systems [abstract]. J Nucl Med. 1999;40(suppl):292P.
6. Strauss LG, Klippel S, Pan L, et al. Assessment of quantitative FDG PET data in primary colorectal tumors: Which parameters are important with respect to tumor detection? Eur J Nucl Med Mol Imaging. 2007;34:868-877. (Pubitemid 46798955)
7. 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. J Nucl Med. 2004;45:1480-1487.
8. 18F-FDG-PET for the evaluation of soft tissue sarcomas: relation to differential diagnosis, tumor grading and prediction of prognosis. Hell J Nucl Med. 2009;12:223-228.
9. Dimitrakopoulou-Strauss A, Strauss LG, Egerer G, et al. Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis. Eur J Nucl Med Mol Imaging. 2010;37:1481-1489.
10. Dimitrakopoulou-Strauss A, Hoffmann M, Bergner R, et al. Prediction of progression-free survival in patients with multiple myeloma following anthracycline-based chemotherapy based on dynamic FDG-PET. Clin Nucl Med. 2009;34:576-584.
11. Dimitrakopoulou-Strauss A, Hoffmann M, Bergner R, et al. Prediction of short-term survival in patients with advanced non-small cell lung cancer following chemotherapy based on 2-deoxy-2-[F-18]fluoro-Dglucose-positron emission tomography: a feasibility study. Mol Imaging Biol. 2007;9:308-317. (Pubitemid 47304781)
12. 18F-fluoro-2-deoxy-D-glucose rate constants in the anesthetized baboon brain with dynamic positron tomography. J Neurosci Methods. 1993;50:263-272.
13. Ohtake T, Kosaka N, Watanabe T, et al. Noninvasive method to obtain input function for measuring tissue glucose utilization of thoracic and abdominal organs. J Nucl Med. 1991;32:1432-1438.
14. Dimitrakopoulou-Strauss A, Strauss LG, Mikolajezyk K, et al. On the fractal nature of dynamic positron emission tomography (PET) studies. World J Nucl Med. 2003;2:306-313.
15. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med. 2008;49(suppl2):24S-42S. (Pubitemid 351948035)
16. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70. (Pubitemid 30046295)
17. 18F-FDG uptake in lung, breast and colon cancer: molecular biology correlates and disease characterization. J Nucl Med. 2009;50:1820-1827.
18. 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading. J Nucl Med. 2001;42:713-720.
19. 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study. J Nucl Med. 2010;51:551-558.
20. 18F-FDG studies: the DKFZ experience. Hell J Nucl Med. 2010;13:18-22.
21. Schellenberg D, Quon A, Minn AY, et al. 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 2010;77:1420-1425.
22. Ueno M, Ohkawa S, Miyakawa K, et al. Usefulness of FDG-PET in predicting the prognosis of advanced pancreatic carcinoma with chemotherapy [abstract]. Proc Am SocClinOncol. 2006;24:18s.
23. Okamoto K, Koyama I, Miyazawa M, et al. Preoperative 18[F]- fluorodeoxyglucose positron emission tomography/computed tomography predicts early recurrence after pancreatic cancer resection. Int J Clin Oncol. 2011;16:39-44.
24. Komar G, Kauhanen S, Liukko K, et al. Decreased blood low with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clin Cancer Res. 2009;15:5511-5517.
25. Mankoff DA, Dunnwald LK, Partridge SC, Specht LM. Blood flow-metabolism mismatch: good for the tumor, bad for the patient. Clin Cancer Res. 2009;15:5294-5296.
26. Specht JM, Kurland BF, Montgomory SK, et al. Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. Clin Cancer Res. 2010;16:2803-2810.
27. Dunnwald LK, Gralow JR, Ellis GK, et al. Tumor metabolism and blood flow by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol. 2008;26:4449-4457.